Ep 86: Tudriqev (RP1) FDA Approval

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V

They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data.

It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(95)

Populært innen Helse

fastlegen
lydartikler-fra-aftenposten
rss-gukild-johaug
psykodrama
hvordan-har-du-det-mann
leger-om-livet
fryktlos
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
rss-ekteskapet
foreldreradet
morten-ramm-lar-kakla-ga-til-du-sovner
rss-garne-damer
hjernesterk
rss-kunsten-a-leve
treningsprat
klimaks
rss-lopedrommen
rss-loping-for-nybegynnere
rss-kull